Ocugen, INC 8-K filings

Ocugen, Inc. will present at the Eyecelerator conference in Park City, Utah on May 2, 2025, and may use the presentation in discussions with investors and analysts.

Ocugen, Inc. reports the resignation of Prabha Fernandes and the decision of Marna Whittington not to stand for re-election, with Satish Chandran and Blaise Coleman nominated as replacements.

Ocugen, Inc. announces the posting of a new investor presentation on its website, providing a corporate update to investors and analysts.

Ocugen reports fourth quarter and full year 2024 financial results, highlighting progress in gene therapy programs and alignment with the FDA on a pivotal trial for Stargardt disease.

Ocugen, Inc. will post an investor presentation on its website on March 3, 2025, for use in discussions with investors and analysts.

Ocugen, Inc. announces the posting of a new investor presentation on its website, which may be used in discussions with investors and analysts.

Ocugen, Inc. enters into a $30 million loan and security agreement with Avenue Capital, issuing shares of common stock and granting conversion rights to the lenders.

Ocugen, Inc. released a presentation for investors, analysts, and other parties, detailing recent developments.

Ocugen, Inc. received a notification from Nasdaq regarding its failure to maintain a minimum share price of $1.00, putting its listing at risk.

Ocugen, Inc. has released an investor presentation detailing clinical trial data and company updates.

Ocugen, Inc. has appointed Ramesh Ramachandran as its new principal financial officer and principal accounting officer, effective November 14, 2024.

Ocugen presented preclinical data at a Nasdaq showcase indicating positive results for their OCU400 gene therapy in treating inherited retinal diseases.

Ocugen has secured a $30 million loan facility with Avenue Capital to fund clinical development and extend its cash runway into the first quarter of 2026.

Ocugen announced its third quarter 2024 financial results, highlighting progress in its gene therapy programs and a strengthened cash position.

Ocugen Inc. released a presentation detailing the progress of its gene and cell therapy programs, including updates on clinical trials and regulatory milestones.

Ocugen announced its second quarter 2024 financial results, highlighted by progress in clinical trials and a recent $32.6 million capital raise.

Ocugen has received FDA approval to begin an expanded access program for OCU400, a gene therapy for adults with retinitis pigmentosa, while a Phase 3 trial is underway.

Ocugen, Inc. has announced a public offering of 30,434,783 shares of its common stock at $1.15 per share, aiming to raise $35 million before expenses.

Ocugen, Inc. has appointed PricewaterhouseCoopers LLP as its new independent registered public accounting firm for the fiscal year ending December 31, 2024, replacing Ernst & Young LLP.

Ocugen Inc. held its 2024 Annual Meeting, electing directors, approving a share increase, and addressing other key proposals.

Ocugen is seeking a new auditor after Ernst & Young declined to participate in the request-for-proposal process for the fiscal year ending December 31, 2024.

Ocugen announced its first quarter 2024 financial results, highlighting progress in its gene therapy programs, including the advancement of OCU400 to Phase 3 clinical trials.

Ocugen, Inc. has declared a dividend of Series C Preferred Stock to common stockholders, granting enhanced voting rights for specific proposals related to increasing authorized common stock and adjusting voting requirements.

The U.S. District Court for the Eastern District of Pennsylvania has dismissed consolidated stockholder derivative lawsuits against Ocugen, Inc. and certain of its agents.

Ocugen has received FDA clearance to begin a Phase 3 clinical trial for its OCU400 gene therapy, targeting a broad range of retinitis pigmentosa (RP) mutations.

Ocugen reports progress in its gene therapy programs, including FDA alignment for a broad indication for OCU400, and provides a financial update for the year ending 2023.

Ocugen, Inc. has identified accounting errors requiring restatement of past financial statements and a delay in filing its 2023 Form 10-K.

The U.S. Court of Appeals for the Third Circuit affirmed the dismissal of consolidated securities class action lawsuits against Ocugen, Inc.

Ocugen announces a board member's departure and a change to the company's bylaws, reducing the quorum requirement for stockholder meetings.

Ocugen, Inc. has announced the appointment of Dr. Huma Qamar as its new Chief Medical Officer, effective March 18, 2024.